- Home
- LNC vs RYTM Comparison
LNC vs RYTM Comparison
Compare LNC & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNC
- RYTM
- Stock Information
- Founded
- LNC 1905
- RYTM 2008
- Country
- LNC United States
- RYTM United States
- Employees
- LNC N/A
- RYTM N/A
- Industry
- LNC Life Insurance
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- LNC Finance
- RYTM Health Care
- Exchange
- LNC Nasdaq
- RYTM Nasdaq
- Market Cap
- LNC 7.9B
- RYTM 6.4B
- IPO Year
- LNC N/A
- RYTM 2017
- Fundamental
- Price
- LNC $39.31
- RYTM $109.71
- Analyst Decision
- LNC Hold
- RYTM Strong Buy
- Analyst Count
- LNC 11
- RYTM 13
- Target Price
- LNC $41.45
- RYTM $110.38
- AVG Volume (30 Days)
- LNC 1.5M
- RYTM 589.3K
- Earning Date
- LNC 10-30-2025
- RYTM 11-04-2025
- Dividend Yield
- LNC 4.67%
- RYTM N/A
- EPS Growth
- LNC N/A
- RYTM N/A
- EPS
- LNC 6.00
- RYTM N/A
- Revenue
- LNC $18,036,000,000.00
- RYTM $156,287,000.00
- Revenue This Year
- LNC $7.05
- RYTM $46.14
- Revenue Next Year
- LNC $4.19
- RYTM $63.37
- P/E Ratio
- LNC $6.42
- RYTM N/A
- Revenue Growth
- LNC 31.97
- RYTM 53.55
- 52 Week Low
- LNC $27.58
- RYTM $45.91
- 52 Week High
- LNC $43.66
- RYTM $113.91
- Technical
- Relative Strength Index (RSI)
- LNC 46.19
- RYTM 64.67
- Support Level
- LNC $37.99
- RYTM $107.37
- Resistance Level
- LNC $40.61
- RYTM $113.56
- Average True Range (ATR)
- LNC 1.03
- RYTM 4.04
- MACD
- LNC -0.13
- RYTM 1.15
- Stochastic Oscillator
- LNC 32.78
- RYTM 78.60
About LNC Lincoln National Corporation
Lincoln National Corp operates multiple insurance and retirement businesses. The company's operating segment includes Annuities; Retirement Plan Services; Life Insurance and Group Protection. Its products include fixed and indexed annuities, variable annuities, universal life insurance (UL), variable universal life insurance (VUL), linked-benefit UL and VUL, indexed universal life insurance (IUL), term life insurance, employer-sponsored retirement plans and services, and group life, disability and dental.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.